Medical-necessity letter template.
A short framework for the letter that supports a named-patient application. A drafting aid, not a substitute for counsel.
A medical-necessity letter is the document in which a treating physician explains, in writing, why a specific therapy is the right choice for a specific patient. Most named-patient pathways require one, and the quality of the letter is a material driver of the regulatory review. The template below is a starting framework. It is deliberately short, because a letter that runs past two pages tends to dilute its own argument. A prescriber should adapt the template to the patient, the indication, and any specific language the destination country expects.
What the letter should establish
Four things, in order. First, that the prescriber is a licensed physician treating the patient and is clinically accountable for the plan of care. Second, that the patient has a specific diagnosis for which the therapy is appropriate under the current evidence and under the applicable label. Third, that locally available alternatives are inadequate for identifiable clinical reasons. Fourth, that the prescriber has considered the cross-border pathway deliberately and is prepared to remain engaged in the patient's care through administration, follow-up, and any pharmacovigilance obligation that arises.
Template text
The following is a starting template. Replace the bracketed fields with case-specific detail; remove or add sections as the case warrants; review the final letter with local counsel or the institution's compliance officer before signing.
[Prescriber letterhead]
Date: [Date]
Re: Medical necessity for [drug name] in [patient name, date of birth, national identifier]
To whom it may concern,
I am [prescriber full name], [specialty] physician at [institution]. I hold active medical licensure [license number, issuing authority], and I am the treating physician of record for [patient name], [date of birth], [identifier], who has been under my care since [date].
[Patient name] has been diagnosed with [diagnosis, including relevant subtype or staging], confirmed by [brief diagnostic basis including key laboratory, imaging, or pathology findings and dates]. The clinical course to date has included [brief treatment history, outcomes, and reasons for moving to the proposed therapy].
On the basis of the foregoing, I have recommended treatment with [drug name, strength, dosage form], at [dose and schedule], for [expected duration]. This recommendation is consistent with [label indication, applicable guideline, or published evidence that supports the plan].
Locally available alternatives are inadequate for this patient because [specific reasons: local unavailability, prior failure on locally available options, contraindication to local options, specific pack or presentation required, or equivalent]. I have considered and discussed with the patient and family the option of remaining on locally available therapy and the option of waiting for local availability, and I have concluded that the clinical situation does not support either option.
The patient and the family have consented to cross-border access to this therapy under a named-patient pathway, have been briefed on the logistics and on the pharmacovigilance obligations that attach, and have executed the accompanying consent document. The therapy will be sourced through a US-licensed specialty wholesale channel under the Drug Supply Chain Security Act, and will be delivered to [receiving institution or clinic] under a documented chain of custody.
I will remain the clinical contact for administration and follow-up, and I will route any observed adverse event through the pharmacovigilance channel supplied by the coordinating pharmacy, in addition to any local pharmacovigilance obligation that applies.
I am available at [contact details] for any clarification the reviewing authority may require.
Sincerely,
[Prescriber name, credentials]
[Institution]
[License number, issuing authority]
Notes on adapting the template
Some destination countries require the letter on a specific letterhead or in a specific language; coordinate with the named-patient coordinator or local counsel before signing. Some require a notarized signature or an apostille; plan the timing accordingly, as apostille procurement can add one to two weeks. Some institutions require internal compliance review before a physician signs a medical-necessity letter for a cross-border case; if this applies, build the internal review into the timeline before the case moves into coordination.
What not to include
A medical-necessity letter should avoid assertions that exceed the prescriber's first-hand knowledge of the patient, comparative claims against other therapies that the prescriber is not prepared to defend on evidence, and any statement about pricing, payment, or commercial relationships. Keep the letter tight on the clinical argument, and let the regulatory and sourcing documentation handle the commercial and logistics facts separately.
Disclaimer
This template is a drafting aid. It does not constitute legal or medical advice. The prescriber and the institution's compliance function are responsible for the final form of the letter and for its compliance with local law and local institutional policy.
Reviewed 2026-04-22 by Reserve Meds’s AI clinical and regulatory review agents. Human pharmacist-in-charge: Altima Care. Next scheduled review: 2026-10-22.